96517-77-0

Upstream product

• 14091-94-2 3-morpholino-1-phenylbut-2-en-1-one 
• 18940-23-3 1-(1-morpholino)-1-phenyl-1-buten-3-one 
• 93-91-4 1-phenylbutan-1,3-dione 
• 54364-12-4 4-methyl-6-phenyl-2-thioxo-1,2-dihydro-pyridine-3-carbonitrile 
• 96517-65-6 2-(3-Cyano-4-methyl-6-phenyl-pyridin-2-ylsulfanyl)-acetamide 
• 79-07-2 Chloroacetamide 

Downstream Products

• 145916-54-7 3-(9-Methyl-7-phenyl-pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-ylamino)-propan-1-ol 
• 145916-53-6 2-(9-Methyl-7-phenyl-pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-ylamino)-ethanol 
• 145916-64-9 7-Methyl-9-phenyl-3,4-dihydro-2H-11-thia-1,4a,6,10-tetraaza-benzo[a]fluorene 
• 145916-63-8 6-Methyl-8-phenyl-2,3-dihydro-10-thia-1,3a,5,9-tetraaza-cyclopenta[a]fluorene 
• 145916-71-8 4-Chloro-9-methyl-7-phenyl-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine 
• 145916-77-4 7-phenyl-9-methyl-pyrido[3',2':4,5]thieno[3,2-d]-pyrimidine-4(3H)-one 

Relevant academic research and scientific papers

3-Amino-6-aryl(or 6-heteroaryl)-thieno?2,3-b|pyridin-2-carboxylic acid amides, pharmaceutical compositions comprising the said and their use as inhibitors of TNFalpha release

3-Amino-6-(hetero)aryl-thieno[2,3-b]pyridin-2-carboxylic acid amide (I) and their solvates, salts, prodrugs formulations, active metabolites or tautomers are new. 3-Amino-6-(hetero)aryl-thieno[2,3-b]pyridin-2-carboxylic acid amide of formula (I) and their

SUBSTITUTED PYRIDO[3',2':4,5]THIENO[3,2-D]PYRIMIDINE-2,4(1 H,3H)-DIONES AND -4(3H)-ONES, SUBSTITUTED THIENO[2,3-D:4,5-D']DIPYRIMIDINE-2,4(1 H,3H)-DIONES AND -4(3H)-ONES, SUBSTITUTED PYRIDO[3',2':4,5]FURO[3,2-D]PYRIMIDINE-2,4(1 H,3H)-DIONES AND -4(3H)-ONES, AND SUBSTITUTED FURO[2,3-D:4,5-D']DIPYRIMIDINE-2,4(1 H,3H)-DIONES AN

The invention relates to novel pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1 H,3H)-diones and -4(3H)-one (X=C-H, Y=S), thieno[2,3-d:4,5-d']dipyrimidine-2,4(1 H,3H)-diones and -4(3H)-one (X=N, Y=S), in addition to pyrido[3',2':4,5]furo[3,2-d]pyrimidine-2,4(1 H,3H)-diones and -4(3H)-one (X=C-H, Y=0) and furo[2,3-d:4,5-d']dipyrimidine-2,4(1 H,3H)-diones and -4(3H)-one (X=N, Y=O) of general formulae 1a and 1b. The invention also relates to a method for the production thereof, pharmaceutical preparations containing said compounds and/or tautomers thereof and physiologically compatible salts which can be produced therefrom and/or solvates thereof, in addition to the pharmaceutical use of said compounds, tautomers thereof, salts or solvates, as inhibitors of TNFa-release.

Synthesis of novel heterocyclic compounds for antitumor and radioprotective activities

Some novel pyridothienoxazine (5); pyridothienopyrimidines (6), (8), (9), (14); pyridothienoimidazole (16); isothiazolopyridine (17), and pyridoisothiazolopyrimidines (18-20) were synthesized. The structural assignment of the prepared compounds were based on microanalytical and spectroscopic evidences. Some prepared compounds were tested in vitro for their antitumor and radioprotective activities. Compounds (7), (12), (17) and (19) showed significant activities against EAC cells, at a concentration of 250μg/ml; while the isothiazolopyridine (17) exhibited radioprotective activity.